Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nankai Univ. ABCG2 compound C7
- Development stage
- Unknown
- Lead developer
- Nankai University
01
Overview
Nankai Univ. ABCG2 compound C7: sourced facts only. name: "Experimental validation identified four compounds (C1/C6/C7/C9) binding ABCG2 with sub-100 μM kd values (5.31-51.35 μM) that potentiate topotecan cytotoxicity." [PMID:40986985]; target: "Experimental validation identified four compounds (C1/C6/C7/C9) binding ABCG2 with sub-100 μM kd values (5.31-51.35 μM) that potentiate topotecan cytotoxicity." [PMID:40986985]; developer: "State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300353, China." [PMID:40986985]
02
Targets
ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on Nankai Univ. ABCG2 compound C7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nankai Univ. ABCG2 compound C7.